Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus more frequent aspirin intake for platelet inhibition
NL-OMON21826Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aspirin in cardiac morbidity, coronary arteriosclerosis, peripheral artery occlusion (PAD) and 1 more (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Platelet aggregation inhibition superiority of twice-daily versus once-daily aspirin. Started Aug 2016; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
cardiac morbiditycoronary arteriosclerosisperipheral artery occlusion (PAD)myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON21826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21826.